U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Anaplastic Oligodendroglioma

MedGen UID:
1631096
•Concept ID:
C4553161
•
Neoplastic Process

Definition

The reemergence of anaplastic oligodendroglioma after a period of remission. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRecurrent Anaplastic Oligodendroglioma

Professional guidelines

PubMed

Treatment updates regarding anaplastic oligodendroglioma and anaplastic oligoastrocytoma.
Khan KA, Abbasi AN, Ali N
J Coll Physicians Surg Pak 2014 Dec;24(12):935-9. PMID: 25523732
Diagnosis and management of oligodendroglioma.
van den Bent MJ
Semin Oncol 2004 Oct;31(5):645-52. doi: 10.1053/j.seminoncol.2004.07.006. PMID: 15497117
Management of oligodendrogliomas.
Shimizu KT, Tran LM, Mark RJ, Selch MT
Radiology 1993 Feb;186(2):569-72. doi: 10.1148/radiology.186.2.8421767. PMID: 8421767

Recent clinical studies

Etiology

Cranial sonolucent prosthesis: a window of opportunity for neuro-oncology (and neuro-surgery).
Del Bene M, Raspagliesi L, Carone G, Gaviani P, Silvani A, Solbiati L, Prada F, DiMeco F
J Neurooncol 2022 Feb;156(3):529-540. Epub 2022 Jan 26 doi: 10.1007/s11060-021-03929-x. PMID: 35079911
Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.
Chinot OL, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X, Braguer D, Martin PM, Grisoli F
J Clin Oncol 2001 May 1;19(9):2449-55. doi: 10.1200/JCO.2001.19.9.2449. PMID: 11331324
Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors.
Husemann K, Wolter M, Büschges R, Boström J, Sabel M, Reifenberger G
J Neuropathol Exp Neurol 1999 Oct;58(10):1041-50. doi: 10.1097/00005072-199910000-00002. PMID: 10515227

Diagnosis

Successful desensitization in a patient with recurrent anaplastic oligodendroglioma presenting with procarbazine-mediated anaphylaxis.
Kayikçi H, Can Bostan Ö, Tuncay G, Cihanbeylerden M, Tüccar Ç, Damadoglu E, Karakaya G, Kalyoncu AF
J Oncol Pharm Pract 2024 Jul;30(5):937-940. Epub 2024 Jan 22 doi: 10.1177/10781552241226861. PMID: 38258352
Spinal cord anaplastic oligodendroglioma with 1p deletion: report of a relapsing case treated with temozolomide.
Wang F, Qiao G, Lou X
J Neurooncol 2011 Aug;104(1):387-94. Epub 2010 Dec 29 doi: 10.1007/s11060-010-0493-1. PMID: 21190059
Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics.
Kronik N, Kogan Y, Vainstein V, Agur Z
Cancer Immunol Immunother 2008 Mar;57(3):425-39. Epub 2007 Sep 7 doi: 10.1007/s00262-007-0387-z. PMID: 17823798Free PMC Article
Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial.
Taliansky-Aronov A, Bokstein F, Lavon I, Siegal T
J Neurooncol 2006 Sep;79(2):153-7. Epub 2006 Jul 20 doi: 10.1007/s11060-005-9020-1. PMID: 16855865
Successful chemotherapy for newly diagnosed aggressive oligodendroglioma.
Macdonald DR, Gaspar LE, Cairncross JG
Ann Neurol 1990 May;27(5):573-4. doi: 10.1002/ana.410270519. PMID: 2360797

Therapy

Successful desensitization in a patient with recurrent anaplastic oligodendroglioma presenting with procarbazine-mediated anaphylaxis.
Kayikçi H, Can Bostan Ö, Tuncay G, Cihanbeylerden M, Tüccar Ç, Damadoglu E, Karakaya G, Kalyoncu AF
J Oncol Pharm Pract 2024 Jul;30(5):937-940. Epub 2024 Jan 22 doi: 10.1177/10781552241226861. PMID: 38258352
Prolonged benefit to pembrolizumab in anaplastic oligodendroglioma patient with mismatch repair deficiency: a case report.
Padovan M, Caccese M, Zagonel V, Lombardi G
Anticancer Drugs 2021 Feb 1;32(2):218-221. doi: 10.1097/CAD.0000000000001011. PMID: 33395066
Spinal cord anaplastic oligodendroglioma with 1p deletion: report of a relapsing case treated with temozolomide.
Wang F, Qiao G, Lou X
J Neurooncol 2011 Aug;104(1):387-94. Epub 2010 Dec 29 doi: 10.1007/s11060-010-0493-1. PMID: 21190059
Temozolomide chemotherapy in recurrent oligodendroglioma.
van den Bent MJ, Keime-Guibert F, Brandes AA, Taphoorn MJ, Kros JM, Eskens FA, Carpentier AF
Neurology 2001 Jul 24;57(2):340-2. doi: 10.1212/wnl.57.2.340. PMID: 11468326
Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.
Chinot OL, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X, Braguer D, Martin PM, Grisoli F
J Clin Oncol 2001 May 1;19(9):2449-55. doi: 10.1200/JCO.2001.19.9.2449. PMID: 11331324

Prognosis

Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics.
Kronik N, Kogan Y, Vainstein V, Agur Z
Cancer Immunol Immunother 2008 Mar;57(3):425-39. Epub 2007 Sep 7 doi: 10.1007/s00262-007-0387-z. PMID: 17823798Free PMC Article
Successful chemotherapy for newly diagnosed aggressive oligodendroglioma.
Macdonald DR, Gaspar LE, Cairncross JG
Ann Neurol 1990 May;27(5):573-4. doi: 10.1002/ana.410270519. PMID: 2360797

Clinical prediction guides

Successful desensitization in a patient with recurrent anaplastic oligodendroglioma presenting with procarbazine-mediated anaphylaxis.
Kayikçi H, Can Bostan Ö, Tuncay G, Cihanbeylerden M, Tüccar Ç, Damadoglu E, Karakaya G, Kalyoncu AF
J Oncol Pharm Pract 2024 Jul;30(5):937-940. Epub 2024 Jan 22 doi: 10.1177/10781552241226861. PMID: 38258352
Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics.
Kronik N, Kogan Y, Vainstein V, Agur Z
Cancer Immunol Immunother 2008 Mar;57(3):425-39. Epub 2007 Sep 7 doi: 10.1007/s00262-007-0387-z. PMID: 17823798Free PMC Article
Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial.
Taliansky-Aronov A, Bokstein F, Lavon I, Siegal T
J Neurooncol 2006 Sep;79(2):153-7. Epub 2006 Jul 20 doi: 10.1007/s11060-005-9020-1. PMID: 16855865
Successful chemotherapy for newly diagnosed aggressive oligodendroglioma.
Macdonald DR, Gaspar LE, Cairncross JG
Ann Neurol 1990 May;27(5):573-4. doi: 10.1002/ana.410270519. PMID: 2360797

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...